Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy

Stock Information for Resverlogix Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Resverlogix Corp.

Resverlogix Announces Change to Its Board of Directors
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
Resverlogix Announces Warrant Repricing and One-Year Extension
Resverlogix Announces Voting Results from the 2023 Meeting of Shareholders
Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
Resverlogix Announces One-Year Extension of Debenture
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.